What are Uvox® Tablets?
Uvox® Tablets are used for the treatment of obsessive-compulsive disorder or depression. Uvox® is a selective serotonin reuptake inhibitor antidepressant that works to increase the level of serotonin to improve mood. Uvox® Tablet is a type of antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) group of medicines. It is prescribed to treat depression, where it helps to make you feel better. This medicine is also used to treat people with obsessive-compulsive disorder.
Uvox® Tablet can be taken with or without food. The dose and how often you need it will be decided by your doctor so that you get the right amount to control your symptoms. Your doctor may start you on a lower dose and increase it gradually. Do not change the dose or stop taking it without talking to your doctor, even if you feel well. Doing so may make your condition worse or you may suffer from unpleasant withdrawal symptoms (anxiety, restlessness, palpitations, dizziness, sleep disturbances, etc).
To get the most benefit, take this medicine regularly at the same time each day. It may take a few weeks before you start feeling better. Let your doctor know if you do not see any improvement even after 4 weeks. Uvox® Tablet is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It works by increasing the levels of serotonin, a chemical messenger in the brain. This improves mood and physical symptoms of depression and also relieves symptoms of obsessive-compulsive disorders.
Fluvoxamine Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in DSM-III-R or DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.
Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable.
Benefits of Uvox® Tablets
- In Depression: Uvox Tablet works by increasing the level of a chemical called serotonin in the brain. This improves your mood, relieves anxiety, tension, and helps you sleep better. It has fewer side effects than older antidepressants. It usually takes 4-6 weeks for this medicine to work so you need to keep taking it even if you feel it is not working. Do not stop taking it, even if you feel better unless your doctor advises you to.
- In Obsessive-compulsive disorder: Uvox Tablet helps relieve symptoms of many anxiety disorders such as obsessive-compulsive disorder by increasing the level of a chemical called serotonin in your brain. It has fewer side effects than older antidepressants and is normally taken once a day. It helps you feel calm with a better ability to deal with problems. Exercise and a healthy diet can also improve your mood. Keep taking the medicine until your doctor advises you to stop.
Dosage and administration
The recommended starting dose for Fluvoxamine Tablets in adult patients is 50 mg, administered as a single daily dose at bedtime. In the controlled clinical trials establishing the effectiveness of Fluvoxamine Tablets in OCD, patients were titrated within a dose range of 100 to 300 mg/day. Consequently, the dose should be increased in 50 mg increments every 4 to 7 days, as tolerated, until the maximum therapeutic benefit is achieved, not to exceed 300 mg per day. It is advisable that a total daily dose of more than 100 mg should be given in two divided doses. If the doses are not equal, the larger dose should be given at bedtime.
Symptoms associated with discontinuation of other SSRIs or SNRIs have been reported. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
Anti-depressant could treat COVID-19?
Could an anti-depressant called fluvoxamine prevent severe disease of COVID-19 if administered early enough? Scientists are curious enough to keep testing as early results from a clinical trial hold some hope.
In the study of 2,100 people, researchers observed a 30 percent reduction in hospitalizations among those who took fluvoxamine. The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function.
Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it’s also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our study suggests fluvoxamine may help fill that niche.
How could an anti-depressant sometimes use to treat obsessive-compulsive disorder help with COVID-19? Fluvoxamine is part of the widely used selective serotonin-reuptake inhibitor cohort of anti-depressants, though it has anti-inflammatory properties, too. Scientists suspect the latter fact could have something to do with stopping the progression of COVID-19.
There are several ways this drug might work to help COVID-19 patients, but we think it most likely may be interacting with the sigma-1 receptor to reduce the production of inflammatory molecules, said senior author Angela M Reiersen, MD, an associate professor of psychiatry. Past research has demonstrated that fluvoxamine can reduce inflammation in animal models of sepsis, and it may be doing something similar in our patients.
Of the 1087 OCD and depressed patients treated with fluvoxamine maleate in controlled clinical trials in North America, 22% discontinued due to an adverse reaction. Adverse reactions that led to discontinuation in at least 2% of fluvoxamine maleate-treated patients in these trials were: nausea (9%), insomnia (4%), somnolence (4%), headache (3%), and asthenia, vomiting, nervousness, agitation, and dizziness (2% each).